Cyprotex PLC is a holding company. The Company and its subsidiaries are engaged in the provision of in vitro and in silico Absorption, Distribution, Metabolism, Excretion, Toxicity (ADMET) and Pharmacokinetic (PK) information to the pharmaceutical and biotechnology industries. It offers a range of different services in the areas of ADME-PK, in vitro toxicology, biosciences, in silico prediction, in vitro skin and ocular testing, endocrine disruption and physicochemical profiling. Its in vitro ADME and drug metabolism and pharmacokinetics (DMPK) services include in vitro metabolism, in vitro permeability and transporters, solubility and physicochemical properties, in vitro protein binding and PK and bioanalysis. It operates mainly in North America, Mainland Europe and the United Kingdom. It serves pharmaceutical, biotech, cosmetics, personal care, household products, chemical, agrochemical and tobacco markets. Its subsidiaries include Cyprotex Discovery Limited and Cyprotex US, LLC.